A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01242111 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

MPS IV A
Mucopolysaccharidosis IVA
Morquio A Syndrome

Interventions

DRUG: BMN 110

Sponsor

BioMarin Pharmaceutical